The randomized, double-blind, 2-arm parallel group Phase II study of BEKINDA™ 12 mg is expected to enroll 120 patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) in 12 clinical sites in the U.S. The U.S. potential market for IBS-D …
Exciting lectures and discussions on therapeutic fusion proteins Laupheim, Germany, April 11, 2016 / B3C newswire / -- The Laupheim Biotech Days – formerly known as <Laupheimer Zelltage> – provide a unique platform for the international exchange of …
Melbourne, Australia, April 4, 2016, / B3C newswire / -- Adherium Limited (ASX: ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, has appointed a new Senior Vice President of Business Development …
The ongoing CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral dose RHB-104 as add-on therapy to interferon beta-1a in 18 …
Vienna, Austria, March 30, 2016 / B3C newswire / -- Zytoprotec, an Austrian biotechnology company, announced today that it has appointed Prof. Dr. Joerg Vienken and Prof. Dr. Norbert Riedel to its Supervisory Board. „We are pleased that with Profs. …
Geneva, Switzerland, and Ingelheim, Germany, March 30, 2016 / B3C newswire / -- Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners …
Garching, Germany and Halle, Germany, March 24, 2016 / B3C newswire / -- ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and targeted carriers, today …
New construction represents an important component of a previously announced investment strategy Ravensburg, Germany, March 22, 2016 / B3C newswire / -- Vetter, a leading global contract development and manufacturing organization (CDMO) for the development …
Scientists can meet with BioPharmaSpec Experts at BioPharma Asia to discuss Characterization Strategies for Accelerating their Biosimilar Development. Jersey, U.K. and Malvern, PA. USA, March 21, 2016 / B3C newswire / -- BioPharmaSpec, a leading contract …
Oss, The Netherlands, March 16, 2016 / B3C newswire / -- ModiQuest Research BV, the Dutch antibody services company, today announced that it will continue its collaboration with Sobi™ aimed at the generation of novel monoclonal antibodies against Sobi …
Innovative PrenaBoxx® provides local NIPT software analysis solution for both NGS- and qPCR-related analysis technologies Constance, Germany, March 16, 2016 / B3C newswire / -- LifeCodexx AG today announced that it has recently teamed up with several …
San Bruno, CA, USA, March 11, 2016 / B3C newswire / -- Selvita, the largest drug discovery company in Central and Eastern Europe, has just opened its West Coast US office, located in San Bruno, CA. Selvita has initiated its US operations in September 2015 …
London, UK and Vienna, Austria, 11 March 2016 / B3C newswire / -- TYG oncology, a UK biotechnology company specializing in hormone neutralization therapy for gastrointestinal cancers, and OncoQR ML GmbH, an Austrian biotechnology company specializing in …
Hudson, New York, USA, March 10, 2016 / B3C newswire / -- Taconic Biosciences, a leading provider of genetically modified solutions to researchers worldwide, will host a five-city symposia series in Europe on Advanced Preclinical Models for Immuno-Oncology …
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC) Amsterdam, The Netherlands and Irvine, CA, USA, March 8, 2016 / B3C newswire / -- Agendia, Inc., a world leader in …
Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company Garching, Germany, March 7, 2016 / B3C newswire / -- ITM Isotopen Technologien München AG (ITM), a specialized …
Peer-reviewed research validates theory that a novel peptide found at raised levels in Alzheimer’s disease brain is primary driver of neurodegeneration Innovative drug prototype shown to block its damaging activity in human cell lines suggests a promising …
Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society London, UK, February 23, 2016 / B3C newswire / -- Dr Steve Bradshaw, …
Elicits Clinically Relevant Immune Response in All Individuals in NHP Model Strong Immune Response Even Under Pancreatic Cancer Chemotherapy Modification of Immune Reaction (Checkpoint Control) Consistently Shown to be Reversible …
Stockholm, Sweden, February 22, 2016 / B3C newswire / -- Nuevolution AB (publ) announces that it will receive a milestone payment of USD 2 million from its drug discovery collaboration with Novartis. In August 2009, Nuevolution and Novartis entered into a …
04 days 21:21:07
